Anti-P53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes
Anti-p53 TCR-Gene
National Cancer Institute (NCI)Cell therapyPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Anti-p53 TCR-Gene cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Fludarabine National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
Anti-P53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →